Figure 2.

Baseline in vitro parameters of GC sensitivity in healthy controls, tREACH, and FLARE patients. The IL-2 assay (A) and GILZ-assay (C) were performed in both tREACH and FLARE patients (bioassays in 32 patients, GC-binding assay in 32 patients, bioassays and GC-binding assay in 27 patients; control groups for the bioassays (n = 20) and binding assay (n = 16) were not the same). As secondary outcome, IL-2 repression (B) and GILZ induction (D) was calculated as follows: <a onClick="popup('http://arthritis-research.com/content/14/4/R195/mathml/M1','MathML',630,470);return false;" target="_blank" href="http://arthritis-research.com/content/14/4/R195/mathml/M1">View MathML</a><a onClick="popup('http://arthritis-research.com/content/14/4/R195/mathml/M2','MathML',630,470);return false;" target="_blank" href="http://arthritis-research.com/content/14/4/R195/mathml/M2">View MathML</a> The numbers of GRs (E) and the affinity of the receptor (F) were determined in FLARE patients only. EC50, half maximal effective concentration. P values were calculated by using ANOVA and Bonferroni post hoc correction; normalized data were used where appropriate.

Quax et al. Arthritis Research & Therapy 2012 14:R195   doi:10.1186/ar4029
Download authors' original image